1. Wagner, E.F.; Schonthaler, H.B.; Guinea-Viniegra, J.; Tschachler, E. Psoriasis: What we have learned from mouse models. Nat. Rev. Rheumatol. 2010, 6, 704–714. [CrossRef] [PubMed]
2. Nestle, F.O.; Kaplan, D.H.; Barker, J. Psoriasis. N. Engl. J. Med. 2009, 361, 496–509. [CrossRef] [PubMed]
3. Kurschus, F.C.; Moos, S. IL-17 for therapy. J. Derm. Sci. 2017, 87, 221–227. [CrossRef] [PubMed]
4. Greaves, M.W.; Weinstein, G.D. Treatment of Psoriasis. N. Engl. J. Med. 1995, 332, 581–589. [CrossRef] [PubMed]
5. Griffiths, C.E.; Barker, J.N. Pathogenesis and clinical features of psoriasis. Lancet (Lond. Engl.) 2007, 370, 263–271. [CrossRef]
6. Van der Fits, L.; Mourits, S.; Voerman, J.S.; Kant, M.; Boon, L.; Laman, J.D.; Cornelissen, F.; Mus, A.M.; Florencia, E.; Prens, E.P.; et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 2009, 182, 5836–5845. [CrossRef]
7. Gilliet, M.; Conrad, C.; Geiges, M.; Cozzio, A.; Thürlimann, W.; Burg, G.; Nestle, F.O.; Dummer, R. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Derm. 2004, 140, 1490–1495. [CrossRef]
8. Geisse, J.; Caro, I.; Lindholm, J.; Golitz, L.; Stampone, P.; Owens, M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J. Am. Acad. Derm. 2004, 50, 722–733. [CrossRef]
9. Lebwohl, M.; Dinehart, S.; Whiting, D.; Lee, P.K.; Tawfik, N.; Jorizzo, J.; Lee, J.H.; Fox, T.L. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Derm. 2004, 50, 714–721. [CrossRef]
10. Wu, J.K.; Siller, G.; Strutton, G. Psoriasis induced by topical imiquimod. Australas. J. Derm. 2004, 45, 47–50. [CrossRef]
11. Fanti, P.A.; Dika, E.; Vaccari, S.; Miscial, C.; Varotti, C. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int. J. Derm. 2006, 45, 1464–1465. [CrossRef] [PubMed]
12. Takikawa, O.; Yoshida, R.; Kido, R.; Hayaishi, O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J. Biol. Chem. 1986, 261, 3648–3653. [PubMed]
13. Mellor, A.L.; Baban, B.; Chandler, P.; Marshall, B.; Jhaver, K.; Hansen, A.; Koni, P.A.; Iwashima, M.; Munn, D.H. Cutting edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 2003, 171, 1652–1655. [CrossRef] [PubMed]
14. Mellor, A.L.; Sivakumar, J.; Chandler, P.; Smith, K.; Molina, H.; Mao, D.; Munn, D.H. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol. 2001, 2, 64–68. [CrossRef]
15. Fallarino, F.; Grohmann, U.; Vacca, C.; Orabona, C.; Spreca, A.; Fioretti, M.C.; Puccetti, P. T Cell Apoptosis by Kynurenines. In Developments in Tryptophan and Serotonin Metabolism; Allegri, G., Costa, C.V.L., Ragazzi, E., Steinhart, H., Laresio, L., Eds.; Springer US: Boston, MA, USA, 2003; pp. 183–190.
16. Kahler, D.J.; Mellor, A.L. T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase. Handb. Exp. Pharm. 2009, 188, 165–196.
17. Llamas-Velasco, M.; Bonay, P.; Jose Concha-Garzon, M.; Corvo-Villen, L.; Vara, A.; Cibrian, D.; Sanguino-Pascual, A.; Sanchez-Madrid, F.; de la Fuente, H.; Dauden, E. Immune cells from patients with psoriasis are defective in inducing indoleamine 2,3-dioxygenase expression in response to inflammatory stimuli. Br. J. Derm. 2017, 176, 695–704. [CrossRef]
18. Trabanelli, S. Indoleamine 2,3-dioxygenase in psoriasis: A defective mechanism. Br. J. Derm. 2017, 176, 570–572. [CrossRef]
19. Ball, H.J.; Yuasa, H.J.; Austin, C.J.; Weiser, S.; Hunt, N.H. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 2009, 41, 467–471. [CrossRef]
20. Fatokun, A.A.; Hunt, N.H.; Ball, H.J. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: Characteristics and potential roles in health and disease. Amino Acids. 2013, 45, 1319–1329. [CrossRef]
21. Yuasa, H.J.; Takubo, M.; Takahashi, A.; Hasegawa, T.; Noma, H.; Suzuki, T. Evolution of Vertebrate Indoleamine 2,3-Dioxygenases. J. Mol. Evol. 2007, 65, 705. [CrossRef]
22. Ball, H.J.; Sanchez-Perez, A.; Weiser, S.; Austin, C.J.; Astelbauer, F.; Miu, J.; McQuillan, J.A.; Stocker, R.; Jermiin, L.S.; Hunt, N.H. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007, 396, 203–213. [CrossRef] [PubMed]
23. Yuasa, H.J.; Hasegawa, T.; Nakamura, T.; Suzuki, T. Bacterial expression and characterization of molluscan IDO-like myoglobin. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2007, 146, 461–469. [CrossRef] [PubMed]
24. Fukunaga, M.; Yamamoto, Y.; Kawasoe, M.; Arioka, Y.; Murakami, Y.; Hoshi, M.; Saito, K. Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: The absence of IDO1 upregulates IDO2 expression in the epididymis. J. Histochem. Cytochem. 2012, 60, 854–860. [CrossRef] [PubMed]
25. Merlo, L.M.F.; Pigott, E.; DuHadaway, J.B.; Grabler, S.; Metz, R.; Prendergast, G.C.; Mandik-Nayak, L. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J. Immunol. 2014, 192, 2082–2090. [CrossRef]
26. Merlo, L.M.F.; Grabler, S.; DuHadaway, J.B.; Pigott, E.; Manley, K.; Prendergast, G.C.; Laury-Kleintop, L.D.; Mandik-Nayak, L. Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clin. Immunol. 2017, 179, 8–16. [CrossRef]
27. Metz, R.; Smith, C.; DuHadaway, J.B.; Chandler, P.; Baban, B.; Merlo, L.M.F.; Pigott, E.; Keough, M.P.; Rust, S.; Mellor, A.L.; et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int. Immunol. 2014, 26, 357–367. [CrossRef]
28. Merlo, L.M.; DuHadaway, J.B.; Grabler, S.; Prendergast, G.C.; Muller, A.J.; Mandik-Nayak, L. IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism. J. Immunol. 2016, 196, 4487–4497. [CrossRef]
29. Asadullah, K.; Sterry, W.; Stephanek, K.; Jasulaitis, D.; Leupold, M.; Audring, H.; Volk, H.D.; Döcke, W.D. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach. J. Clin. Invest. 1998, 101, 783–794. [CrossRef]
30. Hawkes, J.E.; Yan, B.Y.; Chan, T.C.; Krueger, J.G. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J. Immunol. 2018, 201, 1605–1613. [CrossRef]
31. El Malki, K.; Karbach, S.H.; Huppert, J.; Zayoud, M.; Reissig, S.; Schuler, R.; Nikolaev, A.; Karram, K.; Munzel, T.; Kuhlmann, C.R.; et al. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J. Invest. Derm. 2013, 133, 441–451. [CrossRef]
32. Moos, S.; Mohebiany, A.N.; Waisman, A.; Kurschus, F.C. Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. J. Invest. Derm. 2019, 139, 1110–1117. [CrossRef] [PubMed]
33. Mezrich, J.D.; Fechner, J.H.; Zhang, X.; Johnson, B.P.; Burlingham, W.J.; Bradfield, C.A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010, 185, 3190–3198. [CrossRef] [PubMed]
34. Julliard, W.; Fechner, J.H.; Mezrich, J.D. The aryl hydrocarbon receptor meets immunology: Friend or foe? A little of both. Front. Immunol. 2014, 5, 458. [CrossRef] [PubMed]
35. Salimi Elizei, S.; Poormasjedi-Meibod, M.S.; Wang, X.; Kheirandish, M.; Ghahary, A. Kynurenic acid downregulates IL-17/1L-23 axis in vitro. Mol. Cell. Biochem. 2017, 431, 55–65. [CrossRef] [PubMed]
36. Flutter, B.; Nestle, F.O. TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis. Eur. J. Immunol. 2013, 43, 3138–3146. [CrossRef]
37. Asp, L.; Johansson, A.S.; Mann, A.; Owe-Larsson, B.; Urbanska, E.M.; Kocki, T.; Kegel, M.; Engberg, G.; Lundkvist, G.B.; Karlsson, H. Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts. J. Inflamm. 2011, 8, 25. [CrossRef]
38. Sheipouri, D.; Grant, R.; Bustamante, S.; Lovejoy, D.; Guillemin, G.; Braidy, N. Characterisation of the Kynurenine Pathway in Skin-Derived Fibroblasts and Keratinocytes. J. Cell. Biochem. 2015, 116, 903–922. [CrossRef]
39. Scheler, M.; Wenzel, J.; Tüting, T.; Takikawa, O.; Bieber, T.; von Bubnoff, D. Indoleamine 2,3-Dioxygenase (IDO): The Antagonist of Type I Interferon-Driven Skin Inflammation? Am. J. Pathol. 2007, 171, 1936–1943. [CrossRef]
40. Yamamoto, Y.; Yamasuge, W.; Imai, S.; Kunisawa, K.; Hoshi, M.; Fujigaki, H.; Mouri, A.; Nabeshima, T.; Saito, K. Lipopolysaccharide shock reveals the immune function of indoleamine 2,3-dioxygenase 2 through the regulation of IL-6/stat3 signalling. Sci. Rep. 2018, 8, 15917. [CrossRef]
41. Sano, S.; Chan, K.S.; Carbajal, S.; Clifford, J.; Peavey, M.; Kiguchi, K.; Itami, S.; Nickoloff, B.J.; DiGiovanni, J. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 2005, 11, 43–49. [CrossRef]
42. Harris, T.J.; Grosso, J.F.; Yen, H.R.; Xin, H.; Kortylewski, M.; Albesiano, E.; Hipkiss, E.L.; Getnet, D.; Goldberg, M.V.; Maris, C.H.; et al. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 2007, 179, 4313–4317. [CrossRef] [PubMed]
43. Yuasa, H.J.; Ball, H.J.; Ho, Y.F.; Austin, C.J.D.; Whittington, C.M.; Belov, K.; Maghzal, G.J.; Jermiin, L.S.; Hunt, N.H. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases: IDOs from monotremes and marsupials. Comp. Biochem. Physiol. Part B: Biochem. Mol. Biol. 2009, 153, 137–144. [CrossRef] [PubMed]
44. Yuasa, H.J.; Ball, H.J.; Austin, C.J.D.; Hunt, N.H. 1-l-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-d-methyltryptophan. Comp. Biochem. Physiol. Part B: Biochem. Mol. Biol. 2010, 157, 10–15. [CrossRef] [PubMed]
45. Pantouris, G.; Serys, M.; Yuasa, H.J.; Ball, H.J.; Mowat, C.G. Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1. Amino Acids. 2014, 46, 2155–2163. [CrossRef] [PubMed]